Dr. Marla Lipsyc-Sharf reviews her recent session at the 2024 SABCS meeting, discussing biopsy approaches and treatment ...

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

5,6 This test is for patients who have recently been diagnosed with node-negative or node-positive HR+ and HER2- invasive ...

The U.S. National Institutes of Health reports that about 81% of breast cancer patients are initially diagnosed as HER2-negative, a status that can evolve over time. The liquid biopsy test ...

Payers want to make sure patients are getting biopsies done so they can get on the right therapies, said Bhuvana Sagar, MD, Oncology Consultants.

The two companies are co-developing an innovative liquid biopsy test to detect HER2 genetic amplification and protein expression in circulating tumor cells (CTCs) collected from the blood of ...

Over 60% of breast cancer patients have a HER2-negative tissue biopsy when ... ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use ...

The U.S. National Institutes of Health reports that about 81% of breast cancer patients are initially diagnosed as HER2-negative, a status that can evolve over time. The liquid biopsy test developed ...

WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM. Independent findings support ANGLE's HER2 assay development programme. Potential fo ...

TEL AVIV, Israel, Dec. 18, 2024 /PRNewswire/ -- BioView Ltd. (TASE: BIOV), a company developing advanced medical imaging systems for cancer ... liquid biopsy test to detect HER2 genetic ...

Over 60% of breast cancer patients have a HER2-negative tissue biopsy when diagnosed and ... ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for ...